Special Issue "Epigenetic Drug Discovery"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (15 May 2014)
Prof. Dr. Chas Bountra (Website)
Structural Genomics Consortium, University of Oxford, Oxford, OX3 7DQ, UK
Interests: target validation; drug discovery; translational science; structural biology; chemical probes and epigenetics
There is currently significant interest in the discovery and development of epigenetic drugs for many chronic diseases, including cancer, inflammatory, metabolic and neuro-psychiatric conditions. It is hypothesised that these may modify the transcription of many causative genes implicated in the development and maintenance of such diseases, and hence inhibitors of these proteins may deliver novel disease modifying therapeutics. There are questions, however, around the tolerability or therapeutic index of such agents. In this issue we will discuss the latest developments in both academia and industry.
Prof. Dr. Chas Bountra
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access quarterly journal published by MDPI.
- drug discovery
- bromodomain inhibitors
- HMT inhibitors